Adrian Schwarzer

W3-Professor

University Medicine Greifswald

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Adrian Schwarzer is a W3-Professor at Greifswald University Medicine in Germany. His research focuses on hematological malignancies, particularly acute myeloid leukemia, and the mechanisms underlying cancer stem cell self-renewal and drug responsiveness. Recent articles by Professor Schwarzer explore advanced techniques in flow cytometry, the implications of mitochondrial protease activation in B-cell lymphomas, and the potential of gene expression-based approaches in predicting genotoxicity for stem cell therapies.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

jan philippé

Ghent University

BELGIUM

View details

Ute Modlich

Research Laboratory Head

University of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adrian Schwarzer

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia

Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.

Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning

A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.

Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes.

Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.

[Treatment-refractory anaemia in a 35-year-old heart transplant recipient on chronic hemodialysis].

The long non-coding RNA <i>Cancer Susceptibility 15</i> (<i>CASC15</i>) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia.

Collaborators (2)

jan philippé

Ute Modlich

Make your next move.